Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order

Executive Summary

Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.

You may also be interested in...



IPOs Are Back: Liquid Biopsy, Cardio, Dialysis Firms Lead $1.5Bn Charge

Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.

COVID-19: Dialysis Machine Makers Respond To Surge In Demand

Baxter and Fresenius are taking extraordinary steps to respond to the flood of COVID-19 patients requiring continuous renal replacement therapy.

Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs

BioIntelliSense is getting ready to trial its newly FDA-cleared BioSticker in patients at Colorado-based hospital network UCHealth for remote monitoring of vital signs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel